Sutro Biopharma, Inc.
STRO
$20.48
-$0.83-3.90%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -235.10% | 49.34% | 35.45% | -16.54% | 76.05% |
| Total Depreciation and Amortization | -33.58% | -32.74% | -13.06% | 5.61% | 6.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.47% | -22.45% | -3.76% | 216.44% | 111.38% |
| Change in Net Operating Assets | 72.77% | -85.24% | 129.74% | 165.29% | -204.57% |
| Cash from Operations | 14.39% | 37.75% | 63.15% | 40.81% | -573.02% |
| Capital Expenditure | 100.00% | 99.06% | 82.77% | 69.69% | 88.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 626.22% | -200.01% | -78.67% | -72.83% | 103.35% |
| Cash from Investing | 650.43% | -178.41% | -78.62% | -72.85% | 103.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 41,865.45% | -- | -88.36% | -100.00% |
| Repurchase of Common Stock | -596.67% | 11.11% | -179.17% | 66.22% | -62.16% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -596.67% | 156,074.24% | -166.67% | -89.97% | -100.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 54.16% | 118.50% | -149.58% | -97.73% | -265.05% |